|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_on1007290594 |
003 |
OCoLC |
005 |
20231120010226.0 |
006 |
m o d |
007 |
cr cnu|||unuuu |
008 |
171024t20182018enk ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d IDEBK
|d OPELS
|d OCLCF
|d YDX
|d OCLCO
|d UPM
|d MERER
|d OCLCQ
|d D6H
|d DKU
|d GGVRL
|d VT2
|d UWW
|d COO
|d OCLCQ
|d OCLCO
|d U3W
|d LVT
|d LQU
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1007552717
|a 1021268858
|a 1023045893
|a 1035651481
|a 1036275091
|a 1036277436
|a 1097123110
|a 1105188521
|a 1105565025
|a 1175770113
|a 1235835778
|
020 |
|
|
|a 9780128098974
|q (electronic bk.)
|
020 |
|
|
|a 012809897X
|q (electronic bk.)
|
020 |
|
|
|z 9780128098196
|
020 |
|
|
|z 0128098198
|
024 |
8 |
|
|a 14922726
|
035 |
|
|
|a (OCoLC)1007290594
|z (OCoLC)1007552717
|z (OCoLC)1021268858
|z (OCoLC)1023045893
|z (OCoLC)1035651481
|z (OCoLC)1036275091
|z (OCoLC)1036277436
|z (OCoLC)1097123110
|z (OCoLC)1105188521
|z (OCoLC)1105565025
|z (OCoLC)1175770113
|z (OCoLC)1235835778
|
050 |
|
4 |
|a RC582
|
060 |
|
4 |
|a QW 525
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
4 |
|a 616.079
|2 23
|
245 |
0 |
0 |
|a Immunotoxicology, immunopathology, and immunotherapy /
|c edited by M.A. Hayat.
|
264 |
|
1 |
|a London :
|b Academic Press, an imprint of Elsevier,
|c [2018]
|
264 |
|
4 |
|c �2018
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Immunology ;
|v volume 1
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed October 27, 2017).
|
520 |
|
|
|a Immunology, Volume 1: Immunotoxicology, Immunopathology, and Immunotherapy discusses the investment of time, effort and finance that go into making progress in preventing and/or curing serious diseases by using standard treatments (chemotherapy, radiotherapy, surgery, and hormone therapy). The use of these treatments is accompanied by unavoidable, devastating side effects. At the cost of being repetitious, it has to be emphasized that an improved understanding of the immune system, avoidance of unhealthy habits (e.g., smoking, intake of alcohol, perpetual stress, and lack of exercise) and early detection (using biomarkers) are the only three friends we have to at least delay the onset of serious diseases.
|
505 |
0 |
|
|a 1. Molecular mechanisms -- 2. Role in disease and treatment.
|
650 |
|
0 |
|a Immunotoxicology.
|
650 |
|
0 |
|a Immunopathology.
|
650 |
|
0 |
|a Immunotherapy.
|
650 |
|
2 |
|a Immunologic Techniques
|0 (DNLM)D007158
|
650 |
|
2 |
|a Immunotherapy
|0 (DNLM)D007167
|
650 |
|
6 |
|a Immunotoxicologie.
|0 (CaQQLa)201-0120108
|
650 |
|
6 |
|a Immunopathologie.
|0 (CaQQLa)201-0012320
|
650 |
|
6 |
|a Immunoth�erapie.
|0 (CaQQLa)201-0067406
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Immunopathology
|2 fast
|0 (OCoLC)fst00968028
|
650 |
|
7 |
|a Immunotherapy
|2 fast
|0 (OCoLC)fst00968044
|
650 |
|
7 |
|a Immunotoxicology
|2 fast
|0 (OCoLC)fst00968050
|
700 |
1 |
|
|a Hayat, M. A.,
|d 1940-
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Immunotoxicology, immunopathology, and immunotherapy.
|d London : Academic Press, an imprint of Elsevier, [2018]
|z 0128098198
|z 9780128098196
|w (OCoLC)988169702
|
830 |
|
0 |
|a Immunology ;
|v v. 1.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128098196
|z Texto completo
|